SAGE Therapeutics (SAGE) Misses Q1 EPS by 2c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.01), $0.02 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $14.06 million versus the consensus estimate of $14.14 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs